Sunesis Pharmaceuticals (SNSS) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Roth Affirms Sunesis (SNSS) at 'Sell' Following Q2 Report; Risk of Restructuring Remains
July 30, 2015 2:11 PM EDTRoth Capital affirms it Sell rating and $1 price target on Sunesis Pharmaceuticals (Nasdaq: SNSS) following the company's Q2 report earlier Thursday.
Analyst Joseph Pantginis noted that the financial results currently do not impact our investment case, however with a cash... More
